Novartis India launches Pluvicto for PSMA-positive metastatic prostate cancer EP News Bureau Jun 15, 2026 Radioligand therapy approved for eligible patients with PSMA-positive prostate cancer in India
Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030 GlobalData Sep 18, 2024 GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
